The next controllable payload class for targeted oncology.
A first-in-class, light-activatable intracellular payload designed to add an independent spatial control layer to antibody- and peptide-based cancer therapies.
Molecular targeting decides where. Light decides when.
GenLumina is building a modular payload platform for targeted cancer therapies. The platform combines molecular targeting with local light activation, creating two independent layers of control and a route to multiple partner-specific programmes.
Preclinical therapeutics, novel payloads and defined value inflection.
Forbion Ventures focuses primarily on European preclinical to early-clinical therapeutics companies and supports both company creation and existing businesses toward decisive value-inflection points.
Novel payload thesis
GenLumina addresses a challenge Forbion has already backed in oncology: combining established or novel targeting biology with differentiated payload technology.
Defined value inflection
A disciplined evidence plan can test targeted efficacy, biodistribution, safety, therapeutic window and manufacturability before larger clinical capital is committed.
Platform economics
The protected light-controlled payload can support multiple antibody, peptide and ligand programmes while GenLumina retains the underlying platform.
Dutch formation ecosystem
GenLumina's Leiden base creates proximity to Forbion and to its joint-venture formation network with BioGeneration Ventures for seed and early-stage life sciences.
Novel payload science financed toward clinical proof.
Pheon Therapeutics is not presented as a direct technological comparable. It demonstrates that Forbion understands the strategic value of combining differentiated payload technology with targeted oncology programmes and financing the resulting company toward the clinic.
ADC specialist
Forbion co-led Pheon's US$68 million Series A alongside Brandon Capital and Atlas Venture to build a next-generation ADC company.
Novel payload platform
The investment thesis combined new antibodies against attractive targets with proprietary payload technology and a differentiated mechanism of action.
Clinical trajectory
The financing was designed to advance a lead ADC toward clinical proof-of-concept while establishing a broader pipeline of oncology programmes.
Active company building
Forbion took a board role and participated in an international specialist syndicate—capabilities relevant to GenLumina's next stage.
Two layers of precision. One controllable payload.
Molecular targeting determines where the payload goes. Light adds an independent spatial switch that controls where cytotoxic activity is activated.
Molecular targeting
Antibody or peptide directs the payload to tumour cells.
Intracellular delivery
Payload enters and localises within target cells.
Spatial activation
Local light activates the intracellular payload.
Selective killing
Activated payload drives tumour-cell cytotoxicity.
Targeting has advanced. Payload control has not.
Targeted therapies still need to balance potency, systemic exposure and tolerability. GenLumina adds a second, independent gate: the targeting molecule directs the construct, while local light controls where the intracellular payload becomes active.
- In-vitro proof-of-concept in targeted and conjugated approaches
- Activity shown in breast and colorectal cancer models
- Initial in-vivo biodistribution and safety observations within the preclinical programme
- Targeted in-vivo efficacy and dose optimisation
- Expanded biodistribution, safety and therapeutic-window data
- Reproducible conjugation, formulation and manufacturability package
Built to partner broadly.
Modular conjugation to antibodies, peptides and other targeting ligands — designed to work with existing biology and image-guided workflows.
Finance the evidence that unlocks partner programmes.
GenLumina is exploring a staged strategic equity investment toward CTA/IND-enabling preparation, with a specialist lead investor able to contribute oncology expertise, active company building, syndication capacity and access to pharmaceutical partners.
Complete the next in-vivo and product-readiness milestones.
Combine specialist private capital with grants, research funding and partner-funded PoCs.
Create defined routes to option-to-license, co-development and programme licences.
Help build the next differentiated payload platform.
We invite Forbion Ventures to explore a lead investment in GenLumina and to assess how its oncology, payload, Dutch ecosystem and international company-building experience could accelerate the path from focused preclinical validation to pharmaceutical partnering.